Oct. 14, days before the 2025 European Society for Medical Oncology (ESMO) Congress in Berlin, Merck & Co. | Merck has just ...
In Q3, the top 10 TV ad spenders poured a combined $544.8 million into airing their commercials, according to data shared ...
Merck has kicked off construction of a new $3 billion facility at its sprawling manufacturing campus in Elkton, Virginia. | ...
With the lupus treatment landscape poised for a shake-up, Roche is hitting t | Early Monday, Roche announced that the FDA ...
Theravance is educating physicians and payers in anticipation of phase 3 data on ampreloxetine in nOH due to MSA. The company ...
Susan Galbraith, Ph.D., AZ’s oncology R&D chief, attributed Datroway’s strong efficacy to its ADC construct, specifically its ...
After upstaging Merck & Co.’s Keytruda as a monotherapy for patients with first-line non-small cell lung cancer (NSCLC) in ...
Merck’s efforts to make headway in a cancer type that was an elusive target for its superstar oncology med Keytruda prove to ...
Novartis has shared detailed data showing its radioligand therapy Pluvicto could slow the progression of certain hormone-sensitive prostate cancers ahead of a planned application with the FDA. | ...
ESMO: AstraZeneca faces challenge with FDA as Imfinzi, Lynparza miss survival goal in ovarian cancer
More than two years after a positive top-line readout, AstraZeneca has to face the reality that a lack of an overall survival showing for its combo of Imfinzi and Lynparza could prohibit a broader FDA ...
AstraZeneca and Daiichi Sankyo’s star drug Enhertu has delivered a double knockout, showing its ability to stave off early ...
For years, MASH was where drug development dreams went to die. | After Rezdiffra’s approval and Wegovy’s label expansion, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback